Table 1.
Baseline patient characteristics
| BMS‐986231 treatment dosage | |||||
|---|---|---|---|---|---|
| Placebo group (n = 12) | 3 µg/kg/min (n = 6) | 5 µg/kg/min (n = 9) | 7 µg/kg/min (n = 12) | 12 µg/kg/min (n = 7) | |
| Age, years, mean ± SD | 62.7 ± 9.3 | 63.5 ± 3.5 | 61.1 ± 11.4 | 61.6 ± 10.3 | 48.3 ± 17.5 |
| Male, n (%) | 10 (83.3%) | 4 (66.7%) | 8 (88.9%) | 12 (100%) | 5 (71.4%) |
| Race, n (%) | |||||
| White | 8 (66.7%) | 5 (83.3%) | 7 (77.8%) | 9 (75.0%) | 7 (100%) |
| Black or African American | 4 (33.3%) | 1 (16.7%) | 1 (11.1%) | 3 (25.0%) | 0 |
| Primary cardiomyopathy aetiology, n (%) | |||||
| Ischaemic | 6 (50.0%) | 3 (50.0%) | 5 (55.6%) | 6 (50.0%) | 1 (14.3%) |
| Dilated | 4 (33.3%) | 2 (33.3%) | 1 (11.1%) | 4 (33.3%) | 6 (85.7%) |
| Other | 2 (16.7%) | 1 (16.7%) | 3 (33.3%) | 2 (16.7%) | 0 |
| NYHA class at study entry, n (%) | |||||
| III | 9 (75.0%) | 2 (33.3%) | 9 (100%) | 8 (66.7%) | 7 (100%) |
| IV | 3 (25.0%) | 4 (66.7%) | 0 | 4 (33.3%) | 0 |
| Coronary artery disease, n (%) | 7 (58.3%) | 3 (50.0%) | 5 (55.6%) | 8 (66.7%) | 1 (14.3%) |
| Hypertension, n (%) | 8 (66.7%) | 5 (83.3%) | 9 (100%) | 8 (66.7%) | 2 (28.6%) |
| History of arrhythmias, n (%) | 10 (83.3%) | 5 (83.3%) | 7 (77.8%) | 10 (83.3%) | 5 (71.4%) |
| Chronic renal failure, n (%) | 4 (33.3%) | 3 (50.0%) | 2 (22.2%) | 4 (33.3%) | 0 |
| Diabetes mellitus, n (%) | 3 (25.0%) | 4 (66.7%) | 4 (44.4%) | 5 (41.7%) | 1 (14.3%) |
NYHA, New York Heart Association; SD, standard deviation.